fraction (HFpEF), according to its developer Ironwood.
A phase 2, randomized, double-blind, placebo-controlled trial is currently enrolling patients to evaluate praliciguat as a treatment for HFpEF. The trial aims to enroll about 175 patients and intends to evaluate safety and efficacy, and topline data is expected later in 2019.
Praliciguat is an oral, once-daily, soluble guanylate cyclase (sGC) stimulator. It is being studied in patients with diabetic nephropathy and in patients with HFpEF. The condition affects an estimated 3 million Americans, but there are no approved therapies at this time to treat it; however, praliciguat may have the potential to treat the underlying causes by improving nitric oxide signaling, according to the press release from Ironwood.